Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059521 | 0.85 | MAPT (0.37) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL29464291 | 0.85 | TAAR1 (0.55) | TAAR1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL31454642 | 0.85 | MEN1 (0.34) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL20249844 | 0.85 | ACHE (0.43) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL958644 | 0.85 | TAAR1 (0.55) | TAAR1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL31459480 | 0.85 | ACHE (0.43) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL13185299 | 0.85 | MEN1 (0.37) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL534442 | 0.85 | EED (0.37) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL22904169 | 0.85 | MPO (0.39) | TAAR1MEN1KMT2AMAPTHPGD | |
| SCHEMBL23645662 | 0.82 | HPGD (0.36) | TAAR1MEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651923-B | Novel detection method for sphingomyelin transport | 杭州师范大学 | 2024-07-26 | — | — | CN | claimed |
| CN-115651923-A | Novel detection method for sphingomyelin transportation | 杭州师范大学 | 2023-01-31 | — | — | CN | claimed |
| EP-4004186-A1 | METHOD OF OBTAINING MITOCHONDRIA FROM CELLS AND OBTAINED MITOCHONDRIA | LUCA Science Inc. (JP) | 2022-06-01 | — | — | EP | claimed |
| CN-110746322-A | N- [ 3-chloro-4- (1,1, 2-trifluoro-2-trifluoromethoxy-ethyl) -phenyl ] -2, 6-difluoro-benzamidine, preparation method and application | 江苏艾科姆检测有限公司 | 2020-02-04 | — | — | CN | claimed |
| WO-2025264585-A1 | DETECTION OF CANCER BY LIQUID BIOPSY | AQTUAL, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4630464-A1 | FUNCTIONALIZED AND NON-FUNCTIONALIZED AMPHIPHILIC POLYMERS BASED ON POLYACRYLIC ACID FOR THE SOLUBILIZATION, ISOLATION AND MOLECULAR LABELLING OF MEMBRANE PROTEINS IN AQUEOUS MEDIA | Cube Biotech GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| WO-2025101881-A1 | HETEROATOM CONTAINING PEPTIDOMIMETICS TARGETING VIRAL PROTEASES | EMORY UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119874565-A | Mono cyano diaryl ethylene preparation method of class compound | 常州大学 | 2025-04-25 | — | — | CN | disclosed |
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025059080-A1 | METHODS OF DETECTING AUTOIMMUNE CONDITIONS | AQTUAL, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4469458-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-5098922-A | Anticonvulsants | CIBA-GEIGY CORPORATION (US) | 1992-03-24 | — | — | US | disclosed |
| US-5095018-A | Anticonvulsants | BURROUGHS WELLCOME CO. (US) | 1992-03-10 | — | — | US | disclosed |
| EP-0459285-A1 | Ortho-substituted benzyl esters of cyclopropane carboxylic acids | BASF Aktiengesellschaft (DE) | 1991-12-04 | — | — | EP | disclosed |
| US-5045556-A | Aralkyl-4H-1,2,4-triazole derivatives | CIBA-GEIGY CORPORATION (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0402096-A2 | Anticonvulsant pyrazines | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-12 | — | — | EP | disclosed |
| US-4920116-A | ANTIARRHYTHMIA AGENTS | SCHERING A.G. (DE) | 1990-04-24 | — | — | US | disclosed |
| EP-0324791-A1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF. | SCHERING AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| WO-1988002362-A1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | TAAR1 2291/4885MEN1 428/4885KMT2A 2424/4885 |
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | TAAR1 3497/4885MEN1 1370/4885KMT2A 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.